ALTERNATIVE FOR HERBAL PHENTERMINE-ACOMPLIA

Pills of diet of suppressant of appetite- Acomplia (Rimonabant)
Acomplia works on the receptors of CB- 1, which are present every where in a body. Acomplia helps in blocking of these receptors, which in same queue works on the consumption of food in an individual and curbs his appetite. The loss of weight starts takes a place, because the nourishing consumption of individual diminishes absolutely to the extent. It operates on peripheral organs, which play very important part in lipide and metabolism of glucose, including liver, muscles of fat fabric and gastrointestinal tract.
First in the class of CB1 receptors is settled for application for patients with obesity or surplus weight at presence of concomitant factors of risk, such as saccharine diabetes of 2th type or dislipidemiya.

Paris is France, on June, 21, 2006 - Group of sanofi-aventis declared, that European Commission had given out permission on the sale of preparation of ACOMPLIA (rimonabant, 20 mgs/days) in all 25 European states-members of European Union. Preparation of ACOMPLIA, opened and developed the company of sanofi-aventis, is the first in the new class of preparations, urgent CB1 receptors. ACOMPLIA is recommended in addition to the diet and physical loading for treatment of obesity or surplus weight with the concomitant factors of risk, such as saccharine diabetes of 2th type or dislipidemiya.

Permission on the sale of preparation is given out on results consideration of large number of information about efficiency and safety, including information of clinical test of RIO, in which over 6000 patients took part in the whole world; 4500 from these patients inspected during a two-year period. The results of the program RIO showed that reception of preparation of ACOMPLIA in pills for 20 mgs daily considerably reduces weight of body and circumference of waist, and promotes the level of cholesterol of LPVP. It is said in conclusion of the European commission, that in 50% cases the looked after improvement of levels of HbA1c, cholesterol of LPVP and triglitseridov exceeded a result, expected on the basis of one only declines of weight.
Preparation of ACOMPLIA 20 mgs intended for the decline of risk for patients with obesity and surplus weight. Among patients which preparation will appear especially useful, are patients with abdominal obesity (large circumference of waist), sufferings yet and diabetes dislipidemiey.

A sum of risks of development of saccharine diabetes ; he is combination of risk factors on which it is possible to influence. The also new factors of risk, closely associated with abdominal obesity (especially with the indraabdominal'nym deposit of fat), for example, rezistentnost' to insulin, low level of cholesterol of LPVP, and also markers of inflammation: adiponektin and S-reactive of protein.
It is expedient to consult by a doctor before taking of Acomplia and to adhere to the prescribed dosage, to attain the expected results. Acomplia does not need to be taken an expectant mother since it, possibly, causes the defects of birth in a future kid. Acomplia does not need to be also utillized feedings mothers. Although proved not clinically, there is possibility, that this pill of diet, possibly, grows into breast milk. Acomplia masters a liver, so it is recommended, that patients must consult the moderate hepatic worsening by the supplier of health protection before the use of drug.
ACOMPLIA